{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Cohort+B&page=2",
    "query": {
      "intervention": "Placebo Cohort B",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Cohort+B&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T12:34:59.455Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03119649",
      "title": "A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "GLPG2222 50 mg",
          "type": "DRUG"
        },
        {
          "name": "GLPG2222 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "GLPG2222 200 mg",
          "type": "DRUG"
        },
        {
          "name": "GLPG2222 400 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lakefront Biotherapeutics NV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 59,
      "start_date": "2017-03-18",
      "completion_date": "2017-10-19",
      "has_results": true,
      "last_update_posted_date": "2018-11-16",
      "last_synced_at": "2026-09-29T12:34:59.455Z",
      "location_count": 7,
      "location_summary": "Chatom, Alabama • Little Rock, Arkansas • Orlando, Florida + 4 more",
      "locations": [
        {
          "city": "Chatom",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Glenview",
          "state": "Illinois"
        },
        {
          "city": "Portland",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03119649"
    },
    {
      "nct_id": "NCT00444028",
      "title": "Staccato Loxapine Single Dose PK",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "inhaled Loxapine 0.625 mg",
          "type": "DRUG"
        },
        {
          "name": "inhaled Loxapine 1.25 mg",
          "type": "DRUG"
        },
        {
          "name": "inhaled Loxapine 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "inhaled Loxapine 5 mg",
          "type": "DRUG"
        },
        {
          "name": "inhaled Loxapine 10 mg",
          "type": "DRUG"
        },
        {
          "name": "inhaled Placebo (0 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexza Pharmaceuticals, Inc.",
      "sponsor_class": "UNKNOWN",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 50,
      "start_date": "2005-09",
      "completion_date": "2005-11",
      "has_results": true,
      "last_update_posted_date": "2018-11-20",
      "last_synced_at": "2026-09-29T12:34:59.455Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00444028"
    },
    {
      "nct_id": "NCT05797610",
      "title": "A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary IgA Nephropathy"
      ],
      "interventions": [
        {
          "name": "Sefaxersen (RO7434656)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 459,
      "start_date": "2023-08-08",
      "completion_date": "2029-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-09-29T12:34:59.455Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Glendale, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Dimas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05797610"
    },
    {
      "nct_id": "NCT06026397",
      "title": "A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chemotherapy-induced Diarrhea"
      ],
      "interventions": [
        {
          "name": "SK10",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Guangzhou Zhiyi Biotechnology Co., Ltd.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2023-08-01",
      "completion_date": "2024-02-11",
      "has_results": false,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-09-29T12:34:59.455Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06026397"
    },
    {
      "nct_id": "NCT00820950",
      "title": "A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib phosphate cream",
          "type": "DRUG"
        },
        {
          "name": "Dovonex® calcipotriene 0.005%",
          "type": "DRUG"
        },
        {
          "name": "Diprolene® AF betamethasone dipropionate 0.05% cream.",
          "type": "DRUG"
        },
        {
          "name": "Placebo cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 29,
      "start_date": "2007-05-31",
      "completion_date": "2009-04-30",
      "has_results": true,
      "last_update_posted_date": "2022-02-08",
      "last_synced_at": "2026-09-29T12:34:59.455Z",
      "location_count": 6,
      "location_summary": "Vallejo, California • Boston, Massachusetts • Rochester, New York + 3 more",
      "locations": [
        {
          "city": "Vallejo",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00820950"
    },
    {
      "nct_id": "NCT02461160",
      "title": "Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TAK-915 suspension",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "TAK-915 tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 88,
      "start_date": "2015-05-12",
      "completion_date": "2016-08-01",
      "has_results": true,
      "last_update_posted_date": "2019-02-15",
      "last_synced_at": "2026-09-29T12:34:59.455Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02461160"
    },
    {
      "nct_id": "NCT04643067",
      "title": "Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SLE; Drug"
      ],
      "interventions": [
        {
          "name": "KPG-818 low dose in phase 1b",
          "type": "DRUG"
        },
        {
          "name": "KPG-818 mid dose in phase 1b",
          "type": "DRUG"
        },
        {
          "name": "KPG-818 high dose in phase 1b",
          "type": "DRUG"
        },
        {
          "name": "KPG-818 ultra-high dose in phase 1b",
          "type": "DRUG"
        },
        {
          "name": "KPG-818 low dose in phase 2a",
          "type": "DRUG"
        },
        {
          "name": "KPG-818 mid dose in phase 2a",
          "type": "DRUG"
        },
        {
          "name": "KPG-818 high dose in phase 2a",
          "type": "DRUG"
        },
        {
          "name": "KPG-818 Placebo in phase 2a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kangpu Biopharmaceuticals, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2021-06-03",
      "completion_date": "2023-06-29",
      "has_results": true,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-09-29T12:34:59.455Z",
      "location_count": 18,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Clearwater, Florida + 12 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Cutler Bay",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04643067"
    },
    {
      "nct_id": "NCT05476497",
      "title": "Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "VLP Peanut",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Allergy Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 46,
      "start_date": "2022-10-17",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-09-29T12:34:59.455Z",
      "location_count": 10,
      "location_summary": "Tucson, Arizona • Tampa, Florida • Kansas City, Kansas + 7 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05476497"
    },
    {
      "nct_id": "NCT06532942",
      "title": "A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "(Part A) MKND-201",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "(Part B) MKND-201",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "40 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2024-05-28",
      "completion_date": "2024-10-31",
      "has_results": false,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-09-29T12:34:59.455Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06532942"
    },
    {
      "nct_id": "NCT05139810",
      "title": "OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "Donidalorsen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2021-12-03",
      "completion_date": "2023-11-09",
      "has_results": true,
      "last_update_posted_date": "2025-03-06",
      "last_synced_at": "2026-09-29T12:34:59.455Z",
      "location_count": 15,
      "location_summary": "Scottsdale, Arizona • San Diego, California • Santa Monica, California + 12 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05139810"
    }
  ]
}